nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

01.04.2004 | Special Article

Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity Data

verfasst von: E. Vidor, R. Dumas, V. Porteret, F. Bailleux, K. Veitch

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 4/2004

Einloggen, um Zugang zu erhalten

Abstract

Inactivated hepatitis A vaccines were developed in the 1980s and were introduced during the early 1990s. The Aventis Pasteur (AvP) inactivated hepatitis A virus antigen is used in several different vaccine formulations licensed for adults and children. Presented here are the immunogenicity results compiled from 37 clinical trials performed in 20 different countries between 1991 and 2001 in which these vaccines were administered to adults (16 years of age and over), children (aged 12 months–17 years), and infants (younger than 12 months). The accumulated clinical experience with these hepatitis A virus-containing vaccines demonstrates the excellent immunogenicity of this antigen in a wide range of situations. As with other licensed inactivated hepatitis A vaccines, immunological priming is achieved in virtually all vaccinees after a single-dose primary immunization, and it may be reinforced by a booster vaccination administered 6–36 months after the primary vaccination.

André FE, d’Hondt E, Delem AD, Safary A (1992) Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine—rationale and summary of findings. Vaccine 10 (Suppl 1):160–168

Nalin DR (1995) Vaqta. Drug Fut 20:24–29

Vidor E, Fritzell B, Plotkin, S (1996) Clinical development of a new inactivated hepatitis A vaccine. Infection 24:447–458PubMed

Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Glück R, Herzog C (1997) Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15:1209–1213CrossRefPubMed

Feinstone SM, Gust ID (1998) Hepatitis A vaccine. In: Plotkin SA, Orenstein WA (eds) Vaccines. WB Saunders, Philadelphia, pp 650–671

Ambrosch F, Wiedermann G, André FE, Delem AD, Gregor H, Hofmann H, d’Hondt E, Kundi M, Wynen J, Kunz C (1994) Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol 44:452–456PubMed

Overbosh D, Peyron F, Picot N, Varichon JP (2001) Immunogenicity and safety of a combined typhoid fever and hepatitis A vaccine: a comparison of the combined vaccine in a dual-chamber syringe presentation versus the monovalent vaccines. In: Program and abstracts of the 7th International Conference on Travel Medicine. Abstract no. 63

Loebermann M, Kollaritsch H, Chappey O, Chambonneau L, Dumas R, Lafrenz M (2001) Immunogenicity and safety of a combined typhoid fever and hepatitis A vaccine in healthy adults. In: Program and abstracts of the 7th International Conference on Travel Medicine. Abstract no. 64

Van Hoecke C, Lebacq E, Beran J, Prymula R, Collard F (1998) Concomitant vaccination against hepatitis A and typhoid fever. J Trav Med 5:116–120

10.

Piazza M, Safary A, Vegnente A, Soncini R, Pensati P, Sardo M, Orlando R, Tosone G, Picciotto L (1999) Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in childhood vaccination programme. Vaccine 17:585–588CrossRefPubMed

11.

Shapiro CN, Letson GW, Kuehn D, Welty TK, Krause D, Lambert S, Margolis HS (1995) Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. H-61

12.

Lieberman JM, Marcy SM, Partridge J, Ward J (1998) Evaluation of a hepatitis A vaccine in infants: effect of maternal antibodies on the antibody response. In: Program and abstracts of the 36th Infectious Diseases Society of America annual meeting. Abstract no. 76

13.

Troisi CL, Hollinger FB, Krause DS, Pickering LK (1997) Immunization of seronegative infants with hepatitis A vaccine (HAVRIX): a comparative study of two dosing schedules. Vaccine 15:1613–1617CrossRefPubMed

14.

Dagan R, Amir J, Mijalovsky A, Kalmanovitch I, Bar-Yochai A, Thoelen S, Safary A, Ashkenazi S (2000) Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Ped Infect Dis J 19:1045–1052CrossRef

15.

Lopez EL, Contrini MM, Xifro M, Del C, Ceccoli SC, Cattaneo MA, Zambrano B, Dumas R, Rouyrre N, Weber F (2002) Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules. In: Program and abstracts of the 3rd World Congress of Pediatric Infectious Diseases. Abstract no. 25

16.

Lagos R, Munoz A, Dumas R, Pichon S, Zambrano B, Levine M, Vidor E (2003) Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies. Vaccine 21:3730–3733CrossRefPubMed

17.

Nalin DR, Kuter BJ, Brown L, Patterson C, Calandra GB, Werzberger A, Shouval D, Ellerbeck EF, Block SL, Bishop RP, Wiens B, Schwartz SW, Lewis JA, Sitrin RD, Provost PJ, Miller WJ, Ryan JL (1993) Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 18 (Suppl 2):51–55

18.

Vidor E, Fanget B, Montagnon B, Flehmig B (1993) Preliminary results of the clinical development of a highly purified inactivated hepatitis A vaccine. In: Spiess H (ed) Immunprophylaxe gegen Hepatitis A. Deutsches Grünes Kreuz, Marburg, pp 115–166

19.

Garin D, Vidor E, Wallon M, Fanget B, Brasseur P, Delolme H, Caron F, Mojon M, Gravey A, Humbert G, Flehmig B, Peyron F (1995) Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults. Vaccine 13:220–224CrossRefPubMed

20.

Zanetti A, Pregliasco F, Andreassi A, Pozzi A, Vigano P, Cargnel A, Briantais P, Vidor E (1997) Does immunoglobulin interfere with the immunogenicity to Pasteur Mérieux inactivated hepatitis A vaccine? J Hepatol 26:25–30CrossRefPubMed

21.

Walter EB, Hornick RB, Poland GA, Tucker R, Bland CL, Clements DA, Rhamstine CC, Jacobson RM, Brown L, Gress JO, Harris KE, Wiens BL, Nalin DR (1999) Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. Vaccine 17:1468–1473CrossRefPubMed

22.

Leentvaarkuijpers A, Coutinho RA, Brulein V, Safary A (1992) Simultaneous passive and active immunization against hepatitis A. Vaccine 10 (Suppl 1):138–141

23.

Zaaijer HL, Leentvaarkuijpers A, Rotman H, Lelie PN (1993) Hepatitis A antibody titres after infection and immunization—Implications for passive and active immunization. J Med Virol 40:22–27PubMed

24.

Wagner G, Lavanchy D, Darioli R, Pecoud A, Brulein V, Safary A, Frei PC (1993) Simultaneous active and passive immunization against hepatitis A studied in a population of travellers. Vaccine 11:1027–1032CrossRefPubMed

25.

Green MS, Cohen D, Lerman Y, Sjogren MH, Binn LN, Zur S, Slepon R, Robin G, Hoke CH, Bancroft WH, Safary A, Danon Y, Wiener M (1993) Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin. J Infect Dis 168:740–743PubMed

26.

Goilav C, Zuckerman JN, Lafrenz M, Vidor E, Lauwers S, Ratheau C, Benichou G, Zuckerman AJ (1995) Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J Med Virol 46:287–292PubMed

27.

Reuman PD, Kubilis P, Hurni W, Brown L, Nalin D (1997) The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 15:1157–1161CrossRefPubMed

28.

Goubau P, Vangerven V, Safary A, Delem AD, Knops J, d’Hondt E, André FE, Desmyter J (1992) Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. Vaccine 10 (Suppl 1):114–118

29.

Fisch A, Cadilhac P, Vidor E, Prazuck T, Dublanchet A, Lafaix C (1996) Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. Vaccine 14:1132–1136CrossRefPubMed

30.

Linglof T, Van Hattum J, Kaplan KM, Corrigan J, Duval I, Jensen E, Kuter B (2001) An open study of subcutaneous administration of inactivated hepatitis A vaccine (Vaqta) in adults: safety, tolerability, and immunogenicity. Vaccine 19:3968–3971CrossRefPubMed

31.

Williams J, Fox-Leyva L, Christensen C, Fisher D, Schlicting E, Snowball M, Negus S, Mayers J, Koller R, Stout R (2000) Hepatitis A vaccine administration: comparison between ject-injector and needle injection. Vaccine 18:1939–1943CrossRefPubMed

32.

Brindle RJ, Morris CA, Berger R, Kurtz JB (1994) Inadequate response to intradermal hepatitis A vaccine. Vaccine 12:483–484CrossRefPubMed

33.

Dumas R, Forrat R, Lang J, Farinelli T, Loutan L (1997) Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine. Adv Therapy 14:160–167

34.

Beeching N, Clarke P, Kitchin N, Pirmohamed J, Veitch K, Weber F (2003) Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. J Travel Med (in press)

35.

Beran J, Chlibek R, Weber F (2003) A combined dual chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults. Vaccine 21:4650–4654CrossRefPubMed

36.

Zuckerman J, Peyron F, Wallon M, Gay F, Delolme H, Briantais P, Vidor E (1997) Comparison of the safety and immunogenicity of two inactivated hepatitis A vaccines. Adv Therapy 14:116–124

37.

Vidor E, Ratheau C, Briantais P, Vuillier D (1998) Comparison of two immunization schedules with an inactivated hepatitis A vaccine (Avaxim). J Travel Med 5:167–172PubMed

38.

Lolekha S, Pratuangtham S, Punpanich W, Bowonkiratikachorn P, Chimabutra K, Weber F (2003) Immunogenicity and safety of two doses of a pediatric hepatitis A vaccine in Thai children: comparison of 3 vaccination schedules (0–6, 0–12 or 0–18 Months). J Trop Ped 49:333–339

39.

Hornick R, Tucker R, Kaplan KM, Eves KA, Banerjee D, Jensen E, Kuter B (2001) A randomized study of a flexible booster dosing regimen of Vaqta in adults: safety, tolerability, and immunogenicity. Vaccine 19:4727–4731CrossRefPubMed

40.

Kanra G, Yalcin SS, Kara A, Ozmert E, Yurdakok K (2002) Hepatitis A booster vaccine in children after infant immunization. Ped Infect Dis J 21:727–730CrossRef

41.

Iwarson S, Lindh M (2002) Excellent booster response 4–6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis 34:110–111CrossRefPubMed

42.

Kanra G, Yalcin SS, Ceyhan M, Yurdakok K (2000) Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk J Pediatr 42:105–108PubMed

43.

Landry P, Tremblay S, Darioli R, Genton B (2001) Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine 19:399–402CrossRef

44.

Cederna JB, Klinzman D, Stapleton JT (1999) Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine 18:892–898CrossRefPubMed

45.

Zuckerman JN, Kirkpatrick CT, Huang M (1998) Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A. J Travel Med 5:18–22PubMed

46.

Clarke P, Kitchin N, Souverbie F (2001) A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim. Vaccine 19:4429–4433CrossRefPubMed

47.

Bryan JP, Henry CH, Hoffman AG, South-Paul JE, Smith JA, Cruess D, Spieker JM, De Medina M (2000) Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 19:743–750CrossRefPubMed

48.

Herzog C, Angst F, Beck BR, Bovier P, Farinelli T, Glueck R, Hatz C, Loutan L, Steffen R, Zellmeyer M (1997) Boosting healthy travelers with a virosome-formulated hepatitis A vaccine after basic immunization with an alum-adsorbed hepatitis A vaccine. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. 132

49.

Goilav C, Zuckerman J, Lafrenz M, Vidor E, Briantais P, Lauwers S, Ratheau C, Benichou G, Zuckerman A (1997) Persistence of antibodies after inactivated hepatitis A vaccines in a comparative study. J Infect 34:158

50.

Van Herck K, Beutels P, Van Damme P, Beutels M, Van den Dries J, Briantais Ph, Vidor E (2000) Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 60:1–7CrossRefPubMed

51.

Werzberger A, Kuter B, Nalin D (1998) Six years’ follow-up after hepatitis A vaccination. N Engl J Med 338:1160CrossRef

52.

Maiwald H, Jilg W, Bock HL, Löscher T, Sonnenburg FV (1997) Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 15:346–348CrossRefPubMed

53.

Van Damme P, Thoelen S, Cramm M, Degroote K, Safary A, Meheus A (1994) Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 44:446–451PubMed

54.

Wiedermann G, Kundi M, Ambrosch F (1998) Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0–6 schedule). Acta Trop 69:121–125CrossRefPubMed

55.

Van Herck K, Van Damme P (2001) Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 63:1–7CrossRefPubMed

56.

Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, Brown L, Kuter BJ, Nalin DR (1996) Duration of protection from clinical hepatitis A disease after vaccination with Vaqta. J Med Virol 49:235–241CrossRefPubMed

57.

Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C (2002) Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 68:489–493CrossRefPubMed

58.

Ashur Y, Adler R, Rowe M, Shouval D (1999) Comparison of immunogenicity of two hepatitis A vaccines—Vaqta^® and Havrix^®—in young adults. Vaccine 17:2290–2296CrossRefPubMed

59.

Braconier J, Wennerholm S, Norrby R (1999) Comparative immunogenicity and tolerance of Vaqta^® and Havrix^®. Vaccine 17:2181–2184CrossRefPubMed

60.

Bovier P, Althaus B, Glueck R, Chippaux A, Loutan L (1999) Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J Travel Med 6:228–233PubMed

61.

Williams J, Bruden D, Cagle H, McMahon B, Negus S, Christensen C, Snowball M, Bulkow L, Fox-Leyva L (2003) Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 21:3208–3211CrossRefPubMed

62.

Peetermans J (1992) Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine 10 (Suppl 1):99–101

63.

Armstrong ME, Giesa PA, Davide JP, Redner F, Waterbury JA, Rhoad AE, Keys RD, Provost PJ, Lewis JA (1993) Development of the formalin-inactivated hepatitis A vaccine, Vaqta from the live attenuated virus strain CR326F. J Hepatol 18 (Suppl 2):20–26

64.

Gluck R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ (1992) Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 90:2491–2495PubMed

65.

Winokur PL, Stapleton JT (1992) Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 14:580–586PubMed

66.

Vidor E, Xueref C, Blondeau C, Bajard A, Francon A, Goudeau A, Peyron F, Brasseur P, Zuckerman A (1996) Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine. Biologicals 24:235–242CrossRefPubMed

67.

Centers for Disease Control and Prevention (1999) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 48(RR-12):1–31

68.

Direction générale de la santé. Comité technique des vaccinations (1999) La vaccination contre l’hépatite A. In: Guide des vaccinations pp 99–103

69.

Lopez EL, Del Carmen X, Torrado LE, De Rosa MF, Gomez R, Dumas R, Wood SC, Contrini M (2001) Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J 20:48–52CrossRefPubMed

70.

Dagan R, Greenberg D, Goldenbertg-Gehtman P, Vidor E, Briantais P, Pinsk V, Athias O, Dumas R (1999) Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Vaccine 17:1919–1925CrossRefPubMed

71.

Chadha MS, Chitambar SD, Shaikh NJ, Arankalle VA (1999) Exposure of Indian children to hepatitis A virus and vaccination age. Indian J Med Res 109:11–15PubMed

72.

Castillo de Febres C, Petrola C de, Escalona N de, Estopinan M, Bordones G, Zambrano B, Garcia A, Dumas R (2000) Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children. Vaccine 18:656–664CrossRef

73.

Lee CY, Huang LM, Lee PI, Chiu HH, Dumas R, Milcamps B, Lin W (2000) Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children. Southeast Asian J Trop Med Public Health 31:29–36PubMed

74.

Boutin JP, Buisson Y, Chapuis P, Delolme H, Germanetto P, Lamarque D, Lemardeley P, Lemoal JJ, Merouze F, Vidor E (1996) Evaluation of the safety and immunogenicity of a new inactivated hepatitis A vaccine in the French army. Int Rev Armed Forces Med Serv 69:249–254

75.

Vimolket T, Theamboonlers A, Dumas R, Milcamps B, Forrat R, Poovorawan Y (1998) Immunogenicity and safety of a new inactivated hepatitis A vaccine in Thai young adults. Southeast Asian J Trop Med Public Health 29:779–785PubMed

Titel: Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity Data
verfasst von: E. Vidor
R. Dumas
V. Porteret
F. Bailleux
K. Veitch
Publikationsdatum: 01.04.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 4/2004
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-003-1094-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity Data

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2004

Failure of Broth-Based Tests to Detect Methicillin-Resistant Staphylococcus aureus in a Clinical Specimen

Mycobacterium Reverse Hybridization Line-Probe Assay Used to Diagnose Disseminated Mycobacterium haemophilum Infection in a Child with Acute Lymphoblastic Leukemia

Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study

False-Positive Results and Contamination in Nucleic Acid Amplification Assays: Suggestions for a Prevent and Destroy Strategy

Pharmacologic Considerations in Antimicrobial Therapy, with Emphasis on Pharmacokinetics and Pharmacodynamics: Reviews for the Practicing Clinician

African Histoplasmosis Infection with Peritoneal Involvement

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin